Standout Papers
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012)
Immediate Impact
2 by Nobel laureates 11 from Science/Nature 52 standout
Citing Papers
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
Works of David Margolin being referenced
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
2016
Hypogonadotropic Hypogonadism and Cerebellar Ataxia: Detailed Phenotypic Characterization of a Large, Extended Kindred
2002
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David Margolin | 2749 | 829 | 1104 | 1156 | 125 | 3.9k | |
| Nils Koch‐Henriksen | 3555 | 971 | 955 | 887 | 93 | 4.7k | |
| Omar Khan | 2073 | 594 | 707 | 935 | 86 | 3.8k | |
| Aaron Miller | 2841 | 941 | 593 | 668 | 118 | 3.9k | |
| Anders Svenningsson | 3314 | 608 | 1165 | 1095 | 110 | 5.2k | |
| Edward Fox | 3509 | 1309 | 1156 | 1485 | 154 | 5.8k | |
| Daniel Wynn | 2642 | 641 | 765 | 990 | 49 | 3.5k | |
| John R. Corboy | 2247 | 619 | 725 | 517 | 108 | 3.8k | |
| John Rose | 3616 | 1173 | 1582 | 978 | 140 | 5.8k | |
| Lucia Moiola | 3502 | 789 | 639 | 771 | 158 | 4.7k | |
| Vesna Brinar | 2567 | 768 | 565 | 589 | 90 | 3.3k |
All Works
Loading papers...